News | June 07, 2022
NewAmsterdam Pharma shares new data from Phase 2b ROSE Study
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
As per partnership, Carbanio will arrange raw materials and other custom chemicals for Proexp Pharma Pvt. Ltd. through an uninterrupted digital process of the company
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
Subscribe To Our Newsletter & Stay Updated
